Prognostička vrijednost angiogeneze i sadržaja DNA tumorskih stanica u bolesnica sa seroznim rakom jajnika

Ovarian cancer amounts to 5% of all types of cancer in women. Although ovarian cancer accounts for 23% of all female reproductive types of cancer. Almost 50% of all fatalities caused by genital carcinoma are due to ovarian cancer. The lifetime risk for developing ovarian carcinoma is 1.44% of all newborns, or (1/69). Today, the survival rate for women who have developed ovarian cancer is up to 45%. There have been no significant differences in the frequency of development and the survival rate for the ovarian cancer in the past 10 years. Materials and methods. The study included 116 patients treated for serous ovarian cancer between 1993 and 1998 at the Institute for female reproductive oncology, Hospital for female reproductive medicine, the Zagreb Clinical Medical Center. Clinical and pathological prognostic factors and treatment methods for all 116 patients are presented. Aims. To determine the degree of neo-angiogenesis for each individual case of serous ovarian cancer using monoclonal antibody CD-105; to compare the density of blood vessels per area unit to other clinical and pathohistological prognostic factors; to determine the content of DNA (DNA ploidy) using flow cytometry; to compare the link of tumor cells DNA ploidy to other clinical and pathohistological prognostic factors. Results. Using the univariate analysis method, the following was found statistically relevant to the survival ratio: clinical stage (p 2 cm (p 30 (p 30 (P 2 cm (p=0.02) and optimized surgery (p=0.001). Conclusion. Clinical stage, as well as the residual tumor > 2 cm have proved significant prognostic factors for surviving serous ovarian cancer. MVD > 30 is an extremely important statistical factor in determining adverse outcome for the patients with serous ovarian cancer. Introducing MVD screening for the patients with serous ovarian cancer would provide guidance in anticipating tumor's aggressive progress.